Targeting BPOZ-2 in Lewy body disease
Main Author: | Avik Roy |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
Series: | Neural Regeneration Research |
Online Access: | http://www.nrronline.org/article.asp?issn=1673-5374;year=2016;volume=11;issue=6;spage=910;epage=911;aulast=Roy |
Similar Items
-
Synthesis and characterization of palladium(II) and platinum(II) mixed ligand complexes of the type [M(bpozs)2(dppf)]Cl2, bpozs=2-(benzylthio)-5-phenyl-1,3,4-oxadiazole
by: Rezan Ali Saleh, et al.
Published: (2021-03-01) -
BPOZ-2 is a negative regulator of the NLPR3 inflammasome contributing to SARS-CoV-2-induced hyperinflammation
by: Jingfei Li, et al.
Published: (2023-03-01) -
Lewy body disease or diseases with Lewy bodies?
by: Kateřina Menšíková, et al.
Published: (2022-01-01) -
Matters Arising ‘Lewy body disease or diseases with Lewy bodies?’
by: Kurt A. Jellinger
Published: (2022-06-01) -
Reply: Matters Arising ‘Lewy body disease or diseases with Lewy bodies?’
by: Kateřina Menšíková, et al.
Published: (2022-06-01)